Utomilumab is a fully human IgG2 monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9), being investigated for potential clinical anti-tumour activity.
in vivo
Utomilumab (1-10 mg/kg) is well tolerated in the PBMC humanized mouse model[3].
